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Introduction
Although complications after liver transplanta-
tion (LT) have generally become less of a prob-
lem because of advances in surgical techniques, 
organ preservation, and immunosuppressive 
management, biliary complications remain com-
mon [Thuluvath et al. 2005; Sharma et al. 2008; 
Zimmerman et al. 2013]. Of these, biliary stric-
tures and leakage occur most frequently. They are 
influenced by various factors, including the type 
of graft, reconstruction technique, use of biliary 
stents, and other recipient and donor characteris-
tics. In particular, anastomotic biliary strictures 
(ABSs) can result from ischemia at the end of the 
bile duct, causing a fibro-proliferative response 
and small bile leaks that primarily produce peri-
anastomotic fibro-inflammatory responses 
[Verdonk et  al. 2006b; Sharma et  al. 2008; 
Akamatsu et al. 2011].
The rate of post-LT ABS is 5–10% in deceased-
donor liver transplantation (DDLT) and 15–30% 
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Background: Recently, there has been an increase in clinical success rates using 
nonsurgical methods to resolve anastomotic biliary strictures (ABSs) that develop after liver 
transplantation (LT). However, some strictures are particularly refractory and cannot be 
completely resolved by an endoscopic or percutaneous procedure. Consequently, the aim of 
this study was to examine the feasibility and efficacy of using a newly designed fully covered 
self-expandable metal stent (FCSEMS) to resolve refractory ABS.
Methods: A total of 35 patients with an ABS that developed after LT, but could not be resolved 
by an endoscopic or percutaneous procedure, were included in this study. FCSEMSs were 
positioned endoscopically and removed after 2–3 months. After stent removal, the patients 
were followed to assess complications, including re-stenosis.
Results: The mean period from LT to stricture was 13.7 months, and the mean duration of the 
stricture was 31.8 months. The type and mean number of procedures previously attempted 
were endoscopic retrograde cholangiopancreatography (ERCP) (9.1 ± 5.1) in 19 patients 
and percutaneous transhepatic biliary drainage (9.2 ± 4.8) in 16 patients. All patients had 
successful FCSEMS insertions and removals; the mean stent indwelling time was 3.2 months. 
The mean follow-up period was 18.7 months (range: 6.4–37.8 months). Stricture recurrence 
was observed in 6 of 29 patients (recurrence rate: 20.7%). The anastomotic stricture resolved 
with the FCSEMS insertion in 29 of 35 patients (clinical success rate: 82.9%).
Conclusions: The newly designed FCSEMS is a potentially feasible and effective treatment 
for anastomotic strictures that develop after LT but are not amenable to treatment by 
conventional procedures.
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in living-donor liver transplantation (LDLT) 
[Thuluvath et  al. 2005; Graziadei et  al. 2006; 
Sharma et  al. 2008]. Post-LT ABS is often 
regarded as the ‘Achilles’ heel’ of LT because the 
problem is not resolved completely in many cases, 
despite the use of a variety of treatments [Koneru 
et al. 2006]. Treatment strategies for ABS include 
both surgical and nonsurgical approaches, such 
as endoscopic and percutaneous procedures. 
Nonsurgical management has recently become 
more popular. Although the optimal strategy for 
treating ABS remains to be determined, multiple 
sessions of balloon dilatation (BD) followed by 
endoscopic placement of multiple side-by-side 
plastic stents (MPSs) is the most common 
approach [Hsieh et  al. 2013; Kao et  al. 2013]. 
The success rate of BD with MPSs is approxi-
mately 70–91% in patients with DDLT and 60–
100% in patients with LDLT [Thuluvath et  al. 
2005; Zoepf et al. 2006; Pasha et al. 2007; Sharma 
et al. 2008; Seo et al. 2009; Hsieh et al. 2013; Kao 
et al. 2013; Chok et al. 2014]. Moreover, percuta-
neous methods may be used for complex stric-
tures or for strictures that cannot be treated by an 
endoscopic approach [Kim et al. 2009]. The suc-
cess rate of these methods is reportedly as high as 
80% [Roumilhac et al. 2003; Sharma et al. 2008].
With recent technological advances and the intro-
duction of the rendezvous method, the clinical 
success rate for ABS resolution has increased for 
both endoscopic and percutaneous treatments, 
but these methods are not suitable for all patients. 
In such cases, patients may require lifelong 
indwelling percutaneous drainage catheters or, 
alternatively, reassessment for surgery. The aim 
of this study was to evaluate the feasibility and 
efficacy of a newly developed fully covered self-
expandable metal stent (FCSEMS) as treatment 
for post-LT ABS recalcitrant to conventional 
endoscopic and percutaneous methods.
Patients and methods
Patients
Between August 2014 and July 2015, 35 patients 
with one or more post-LT anastomotic strictures 
received the newly modified FCSEMS by endo-
scopic insertion. The patients were referred to 
our institution from three university hospitals. 
Previously, endoscopic management was initially 
performed to resolve strictures. The percutane-
ous approach was performed if endoscopic stent 
insertion failed. As many plastic stents as possible 
were inserted for maximal dilation. Plastic stents 
or percutaneous transhepatic biliary drainage 
(PTBD) catheters were inserted for 2–3 months. 
Refractory strictures were defined as unresolved 
strictures after repeated plastic stent or PTBD 
catheter replacement, regardless of the number of 
procedures performed over 1 year, and the 
FCSEMSs were used in these patients. The inclu-
sion criteria for enrollment were an age of 18 
years or older, one or more bilio-biliary ABSs 
after LT, and one or more refractory ABSs 
amendable to conventional endoscopic and per-
cutaneous methods. The exclusion criteria were a 
contraindication to an endoscopic procedure and 
a suspected malignant stricture. The data gath-
ered following FCSEMS insertion were evaluated 
retrospectively. The Institutional Review Board 
at Gangnam Severance Hospital, South Korea, 
approved this study. All participants provided 
written informed consent.
Stents
The FCSEMS (Kaffes®, Taewoong Medical, 
Seoul, Korea) used in this study has a central 
‘waist’. The stent is 10 mm in diameter at each 
end with gradual tapering to a central diameter of 
8 mm (Figure 1). This design was developed to 
prevent stent migration. It has three radiopaque 
markers for precise positioning of the stent at the 
stricture site. The stents used in this study were 4, 
5, or 6 cm long, depending on the stricture length. 
The stents had a diameter of 6, 8, or 10 mm, and 
the delivery catheter had a diameter of 8.5 Fr. A 
retrievable radiopaque string, 10 cm in length, 
was located at the end of the stent to facilitate its 
removal by standard endoscopic biopsy forceps.
Procedure
Endoscopic retrograde cholangiopancreatogra-
phy (ERCP) was performed on all patients using 
a video duodenoscope (JF240 or TJF240; 
Olympus Optical, Tokyo, Japan; Figure 2). The 
previously inserted PTBD catheter or plastic 
stent was removed. Patients who had previously 
undergone endoscopic sphincterotomy (EST) 
were not treated again, but patients who only had 
a PTBD catheter did undergo EST. The guide-
wire was inserted through the stricture site after 
selective cannulation. The position and length of 
the stricture were measured using a cholangio-
gram, and the stent size required to cover the 
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stricture was determined. After moving the metal 
stent to the stricture site, the central label consist-
ing of three radiopaque markers was located 
adjacent to the center of the stricture, and the 
stent was then deployed by means of a conven-
tional self-expandable metal stent (SEMS). The 
Figure 1. Structure of a FCSEMS. The stent has a central ‘waist’ at the mid-portion and three radiopaque 
markers to allow the radial force of the metallic stent to be directed maximally to the center of the stricture, 
hence inhibiting migration. The fully covered short stent has a long, platinum, radiopaque-marked retrieval 
string. The stent imparts pressure over a large area of the normal duct and reduces the risk of necrosis and 
fibrosis. The long string with vivid platinum markers facilitates removal of the stent from its location high in 
the common bile duct.
Figure 2. Insertion procedure for a FCSEMS. (A) After removing the patient’s drainage catheter or plastic 
stent, a cholangiogram is performed to visualize the shape and length of the stricture site. (B) The FCSEMS 
is inserted at the stricture site, and the insertion site of the plastic stent (used to prevent cholangitis) 
is determined based on the presence of a bile duct stone or sludge. (C) After an indwelling time of 2–3 
months, the FCSEMS is removed by grasping the retrieval string using biopsy forceps (color figure). (D) The 
cholangiogram demonstrates resolution of the stricture.
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stent covered the stricture sufficiently, as con-
firmed by visualization of the two radiopaque 
markers on either side of the stent.
If the stricture was too tight to introduce the cath-
eter, it was dilated using a balloon dilator (6 mm, 
Hurricane™, Boston Scientific, Natick, MA, 
USA) or a tapered tip bougie dilator (Soehendra 
biliary dilation catheter™, Cook Medical, 
Bloomington, IN, USA). A plastic stent was also 
inserted if obstruction of a branch of the bile duct 
by the FCSEMS was suspected. If multiple stric-
tures were present, multiple FCSEMSs were 
inserted at each stricture site. Antibiotics (1 g 
cefoperazone-sulbactam intravenously, or 200 
mg ciprofloxacin intravenously for patients with 
allergies) were administered routinely before and 
after each procedure.
Patient follow up
After stent insertion, patients were monitored in 
our outpatient department for clinical symptoms, 
abnormal laboratory findings, and signs of com-
plications, including cholangitis. An abdominal 
X-ray was taken 1 month after stent insertion to 
detect any stent migration. The FCSEMSs were 
maintained for 2–3 months and then removed 
using endoscopic biopsy forceps. Resolution of 
the ABS was evaluated at stent removal, and a 
new FCSEMS was reinserted if the stricture was 
not completely resolved. Clinical symptoms and 
laboratory test results were recorded at 3-month 
intervals after stent removal to monitor for re-
stenosis. If re-stenosis was suspected, one or more 
of the following tests were performed: computed 
tomography, magnetic resonance cholangiopan-
creatography, or a diisopropyl iminodiacetic acid 
scan. A new FCSEMS was reinserted if re-steno-
sis was confirmed.
Statistical analysis
The continuous variables were expressed as means, 
standard deviations, and ranges. Categorical vari-
ables were summarized as frequencies and per-
centages. Outcomes, success, and recurrence rate 
were expressed as binary data.
Results
The FCSEMS was inserted endoscopically in 35 
patients with ABS after LDLT. Basic patient 
characteristics are shown in Table 1. The most 
common indication was hepatocellular carcinoma 
secondary to hepatitis B virus. The mean period 
Table 1. Basic patient characteristics.
Characteristic Value
Number of patients 35
Age (year, mean ± SD) 56.6 ± 8.9
Male : female 27 : 8
Diagnosis  
 HCC : LC : LC + HCC 20 : 9 : 6
Cause  
 HBV : alcohol : HCV 29 : 5 : 1
Duration between LT and stricture [months, mean ± SD (range)] 13.7 ± 25.9 (10.2–110.1)
Duration of stricture [months, mean ± SD (range)] 31.8 ± 22.1 (12.8–92.4)
No. of strictures  
 Single : multiple 28 : 7
Previous procedures [no. of patients (no. of interventions, mean ± SD)]  
 ERCP 19 (9.1 ± 5.1)
 PTBD 16 (9.2 ± 4.8)
  PTBD only 5 (9.4 ± 7.6)
  ERCP + PTBD 11 (8.8 ± 3.5)
DDLT, deceased-donor liver transplantation; ERCP, endoscopic retrograde cholangiopancreatography; HBV, hepatitis B 
virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LC, liver cirrhosis; LDLT, living-donor liver transplantation; 
LT, liver transplantation; No., number; PTBD, percutaneous transhepatic biliary drainage; SD, standard deviation.
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between LT and stricture appearance was 13.7 
months, and the mean duration of the stricture 
was 31.8 months. A total of 7 patients (20%) had 
complex ABSs and each had a total of 2 stric-
tures. Overall, two FCSEMSs were inserted into 
these patients, one into each stricture (Figure 3). 
The type and mean (± standard deviation) num-
ber of interventions previously attempted in the 
patients were as follows: 19 patients underwent 
previous ERCPs (9.1 ± 5.1 interventions), and 
16 underwent previous PTBDs (9.2 ± 4.8 inter-
ventions). Among the latter group of patients, the 
5 who underwent PTBD alone had a mean of 9.4 
interventions, and the 11 who received both 
PTBD and ERCP underwent a mean of 8.8 
interventions.
The mean follow-up period was 18.7 months, and 
the mean FCSEMS indwelling duration was 3.2 
months (Table 2). The only early (within 1 month 
of insertion) complication was proximal stent migra-
tion. Late (>1 month after insertion) complications 
were stent-related jaundice, cholangitis, and an 
intrahepatic bile duct (IHD) stone. These compli-
cations resolved with stent removal and reinsertion 
of the FCSEMS. Sludge was found in 11 patients 
(31.4%) at stent removal and a common bile duct 
(CBD) or IHD stone in 12 patients (34.3%) (Figure 
4). A plastic stent was additionally inserted in 14 
patients (40%) to help prevent obstruction of bile 
duct branch due to the presence of the FCSEMS. 
Balloon dilation, dilation with a tapered tip bougie, 
or both were performed in 8 patients (22.9%) in 
whom the FCSEMS was not easily deployed 
because of a particularly narrow stricture. Insertion 
and removal of the FCSEMS were technically pos-
sible in all enrolled patients (Table 3). Re-stenosis 
occurred in 6 patients (17.1%) at a mean duration 
of 5.8 months after stent removal. The short-term 
clinical success rate of FCSEMS was thus 82.9%. 
In those patients with re-stenosis, an additional 
FCSEMS was inserted and removed after a 
3-month indwelling period, which resolved the 
stricture recurrence. No statistically significant 
Figure 3. Insertion procedure for multiple FCSEMSs. (A) Previously inserted plastic stents are removed 
endoscopically. (B) The cholangiogram shows multiple anastomotic strictures at the posterior and inferior 
intrahepatic ducts. (C) The strictures are dilated using a balloon dilator to allow passage of the FCSEMSs. (D) 
The FCSEMSs are inserted sequentially into the stricture sites. (E) After an indwelling time of 2–3 months, 
the FCSEMSs are removed by grasping the retrieval strings using biopsy forceps. (F) The cholangiogram 
demonstrates resolution of the multiple strictures.
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Table 2. Clinical outcomes of FCSEMS procedures.
Clinical outcome Value
Balloon dilatation before stent insertion [no. of patients (%)] 8/35 (22.9)
Single SEMS versus double SEMS (no. of patients) 28/7
SEMS only: SEMS + PS (no. of patients) 21/14
FCSEMS stent  
 Length (cm, mean ± SD) 4.2 ± 0.6
 Width (mm, mean ± SD) 7.4 ± 1.5
Duration of stent indwelling [months, mean ± SD (range)] 3.2 ± 1.4 (1.0–6.7)
Sludge formation at stent removal [no. of patients (%)] 11/35 (31.4)
CBD or IHD stone formation at stent removal [no. of patients (%)] 12/35 (34.3)
Follow-up period [months, mean ± SD (range)] 18.7 ± 8.3 (6.4–37.8)
Complications 14.3 (5/35)
 Early complications (⩽1 month) 1
  – stent migration 1
 Late complications (>1 month) 4
  – jaundice 1
  – stent migration 1
  – cholangitis 2
CBD, common bile duct; FCSEMS, fully covered self-expandable metal stent; IHD, intrahepatic bile duct; No., number; 
SD, standard deviation; SEMS, self-expandable metal stent.
Figure 4. Photographs showing sludge or stone formation at stent removal. After the stent is removed, sludge 
(A) or small stones (B) are found and removed using a balloon catheter.
Table 3. Success and recurrence outcomes of FCSEMS procedures.
Outcome Value
Technical success rate [no. of patients (%)] 35/35 (100)
Clinical success rate [no. of patients (%)] 29/35 (82.9)
Recurrence rate [no. of patients (%)] 6/29 (20.7)
Duration between recurrence and stent removal [months, mean ± SD (range)] 5.8 ± 2.4 (3.1–10.2)
Treatment after recurrence of stricture  
 Second FCSEMS insertion 6/6 (100)
FCSEMS, fully covered self-expandable metal stent; no., number; SD, standard deviation.
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factors were found to be associated with the response 
to FCSEMS in univariate and multivariate analyses. 
However, there was a tendency for patients with 
single strictures to have a higher response rate com-
pared with patients with multiple strictures in the 
multivariate analysis (Table 4, p = 0.054).
Discussion
The clinical success rate of the newly modified 
FCSEMS was 82.9%, which was high compared 
with that of conventional methods, because this 
study was performed in recalcitrant strictures as 
opposed to typical strictures in previous studies 
(Tables 5 and 6). The recurrence rate was similar 
to that of conventional self-expandable metal 
stents (SEMs) [Traina et al. 2009; Chaput et al. 
2010; Sauer et  al. 2012; Cerecedo-Rodriguez 
et al. 2013]. Endoscopic treatments for ABS show 
high success rates (70–100%) in DDLT patients 
and somewhat lower rates (60–91%) in LDLT 
patients [Graziadei et al. 2006; Pasha et al. 2007; 
Sharma et al. 2008; Akamatsu et al. 2011; Albert 
et al. 2013; Hsieh et al. 2013; Chok et al. 2014]. 
Reported recurrence rates are approximately 
0–20%, and recurrences are usually managed by 
repeat endoscopic stent placement [Graziadei 
et al. 2006; Gomez et al. 2009; Kato et al. 2009; 
Seo et  al. 2009; Chok et  al. 2014]. Generally, 
post-LT ABS that occurs 1–2 months after LT 
results from transient narrowing caused by post-
operative edema and inflammation [Verdonk 
et al. 2006a]. This type of early ABS shows a good 
response to BD with temporary stent placement 
[Thuluvath et  al. 2005; Sharma et  al. 2008]. 
Conversely, treatment is more difficult for late 
Table 4. Univariate and multivariate analyses assessing factors associated with the response to FCSEMSs in 
refractory strictures after LDLT.
Total patients, 
n
Clinical success,
n (%)
Univariate
p-value
Multivariate
p-value
Sex 0.694 0.733
 Male 27 22 (81.4)  
 Female 8 7 (87.5)  
Age, years 0.973 0.244
 ⩾50 29 24 (82.7)  
 <50 6 5 (83.3)  
Duration of stricture 0.166 0.077
 ⩾12 months 30 26 (86.6)  
 <12 months 5 3 (60.0)  
Previous number of procedures (n) 0.912 0.998
 ⩾6 24 20 (83.3)  
 <6 11 9 (81.8)  
Multiple strictures 0.061 0.054
 Yes 7 4 (57.1)  
 No 28 25 (89.2)  
Indwelling duration 0.817 0.208
 <3 months 16 13 (81.3)  
 ⩾3 months 19 16 (84.2)  
Stone or sludge† 0.336 0.181
 Yes 23 18 (78.3)  
 No 12 11 (91.7)  
Plastic stent insertion 0.585 0.675
 No 21 18 (85.7)  
 Yes 14 11 (78.6)  
Balloon dilatation 0.100 0.546
 No 27 24 (88.9)  
 Yes 8 5 (62.5)  
†Stone or sludge was found at removal of metal stent.
FCSEMS, fully covered self-expandable metal stent; LDLT, living-donor liver transplantation.
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strictures, which occur in the majority of patients. 
These strictures are generally caused by fibrotic 
scarring from ischemia near the bile duct anasto-
mosis site [Verdonk et al. 2006b], which makes 
them more difficult to dilate. Therefore, late ABS 
is managed more aggressively, with periodic 
ERCP sessions every 2–3 months and a longer 
duration of stent insertion, sometimes involving 
the use of stents suitable for a prolonged period of 
time (12–24 months) [Kao et al. 2013]. The stric-
tures treated in this study were refractory ABSs 
because they occurred at least 6 months after LT 
and had failed to resolve after more than 9 
attempts using conventional methods. As these 
were clearly difficult situations, treatment using 
the FCSEMS can be considered to have a rela-
tively high success rate.
Although endoscopic BD with MPS management 
is less invasive and shows a high success rate, its 
primary disadvantage is that it requires repeat 
ERCPs every 3–4 months for 1–2 years [Kao et al. 
2013; Fernandez-Simon et  al. 2014]. The 
FCSEMS may reduce the overall number of pro-
cedures (including ERCP, PTBD, or both) 
required to resolve ABS. In this study, the previ-
ous mean number of ERCP or PTBD interven-
tions was >9, whereas the mean number of 
FCSEMS interventions was approximately 1.3. 
Furthermore, post-LT complex ABSs may have 
characteristics that are distinct from those of 
benign biliary strictures. The ABS angle is acute 
and the IHD is narrow, such that insertion of mul-
tiple plastic stents may be difficult, and it may be 
possible to insert only one or two plastic stents. 
These limitations may hinder sufficient dilation of 
the stricture. Moreover, the inserted plastic stent 
may easily migrate to a proximal or distal portion 
because the center of the plastic stent cannot be 
placed in the center of the ABS stricture.
There have been attempts to overcome the limi-
tations of periodic plastic stent replacements 
using temporary single-session SEMS placement 
as an alternative [Traina et al. 2009; Sauer et al. 
2012; Tarantino et al. 2012; Cerecedo-Rodriguez 
et  al. 2013; Kao et  al. 2013]. However, since 
SEMSs exhibit higher migration rates and vari-
able results, they have been unable to achieve 
consistently superior resolution of ABS com-
pared with maximal plastic stent therapy 
[Kahaleh et al. 2013; Kao et al. 2013]. The ABS 
resolution rate is 80–95% when SEMS patency 
is maintained for at least 3 months and 94–100% 
when dilation and plastic stent treatments per-
sist for 12 months [Kao et al. 2013]. Although 
the clinical success rate of biliary stricture treat-
ment using SEMS was high at 86.4–100%, the 
migration rate (4–37%) and complication rate 
(0–41%) were also relatively high [Kim et  al. 
2010; Tarantino et  al. 2012; Kao et  al. 2013]. 
The main concern in using covered SEMSs is 
migration and the risk of occluding secondary 
branch ducts or the pancreatic duct, which could 
cause cholangitis or pancreatitis. Mucosal hyper-
plasia-induced strictures can occur in the proxi-
mal uncovered end of partially covered SEMSs 
[Kahaleh et al. 2008]. Moreover, SEMS removal 
is labor-intensive and can occasionally cause 
mucosal ulceration and bleeding from damage 
caused by anti-migration systems (e.g. anchor 
fins) [Mahajan et  al. 2009]. Therefore, a new 
type of fully covered FCSEMS  without a poten-
tially damaging anti-migration system is required 
for benign biliary strictures.
The specific modified FCSEMS used in this 
study has a central waist to prevent migration and 
a long string to facilitate removal using standard 
endoscopic biopsy forceps. The FCSEMS has a 
diameter of 10 mm at each end and gradually 
tapers to a center that is 8 mm in diameter. In 
addition, radiopaque markers in the center of the 
stent allow the center of the stricture to match the 
center of the stent, so the radial force of the stent 
can be directed maximally to the center. The pur-
pose of these modifications is to help prevent 
migration, which is the primary problem with 
FCSEMSs. Using the shortest possible stent 
length to optimize the stent length along the stric-
ture length imparts pressure over a large area of 
the duct and reduces the potential risk of necrosis 
and fibrosis, as well as obstruction of a separate 
branch. The stent used in this study was a short 
fully covered metal stent restricted to the stricture 
site, whereas the distal end of the traditional long 
stent overlaps into the duodenum. As a result, 
longer stents can cause pancreatitis, migration, 
and gastrointestinal content reflux, whereas the 
modified stent reduces the risk of these adverse 
effects. The long string of the short stent, with 
vivid platinum markers, facilitates its removal. 
These structural characteristics of the modified 
FCSEMS can be expected to improve the clinical 
resolution of post-LDLT ABS and reduce the 
number of complications. However, sludge or 
stone formation, with a resulting risk of cholangi-
tis occurred relatively frequently in this study 
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using the modified FCSEMS. Although the defi-
nite cause or mechanism could not be ascer-
tained, we assumed that the FCSEMS could 
promote obstruction of branches of the bile duct 
and cholestasis. Although the stent is as short as 
possible, it might still block a side branch duct. 
Later in our study, we inserted an additional plas-
tic stent in an attempt to resolve these sludge or 
stone formation issues and to prevent cholangitis 
following obstruction of the side branch duct.
It has been reported that SEMSs are effective in 
patients with post-LT ABS, and there are argu-
ments for employing this as the initial treatment 
method [Traina et al. 2009; Tarantino et al. 2012; 
Kao et  al. 2013]. In previous studies [Kahaleh 
et al. 2008; Traina et al. 2009; Sauer et al. 2012; 
Tarantino et al. 2012; Cerecedo-Rodriguez et al. 
2013; Kao et al. 2013; Kaffes et al. 2014]. MPSs 
showed a stricture resolution rate very similar to 
that for SEMSs. Moreover BD with MPS treat-
ment has a good clinical success rate and low 
recurrence rate in ABS occurring within 1 month 
of LT [Thuluvath et al. 2005; Hsieh et al. 2013; 
Kao et al. 2013]. Therefore, FCSEMSs may be a 
salvage treatment if plastic stenting treatment 
fails [Traina et  al. 2009; Curcio et  al. 2012; 
Tarantino et  al. 2012], and the results of this 
study show that FCSEMSs are effective in treat-
ing refractory post-LT ABS that has not resolved 
with more conventional methods. Further studies 
are required to investigate the feasibility and 
effectiveness of using FCSEMSs as the initial 
treatment for post-LT ABS.
The limitations of this study include its retrospec-
tive design, as well as the additional plastic stent 
insertion and BD procedures that were performed 
in some patients. The plastic stent insertions were 
necessary to prevent sludge or stone formation 
and possible blocking of other intrahepatic duct 
biliary drainage by the covering membrane. A fur-
ther limitation is that the follow-up data are too 
short-term to fully evaluate the rate of re-stenosis. 
Furthermore, our indwelling time for the 
FCSEMS was 2–3 months, which may have 
increased the recurrence rate if this was not long 
enough to resolve the stricture. Further studies 
with long-term follow up of FCSEMS in post-LT 
ABS are needed, and large-scale prospective 
studies will be necessary to establish the most 
effective indwelling duration of FCSEMSs to 
overcome elastic recoil at the stricture site and 
reduce the recurrence rate of post-LT ABS.
Treatment with endoscopic methods, percutane-
ous procedures, or both for ABSs after LT have 
been highly successful. The success rate has fur-
ther increased because of the rendezvous method 
combined with an endoscopic approach, along 
with advancements in cutting balloons, catheter 
development, and guidewire techniques. However, 
if both approaches fail, the FCSEMS has emerged 
as a new salvage treatment option, with reasonable 
efficacy and feasibility. The clinical success rate 
for treating post-LT ABS, regarded as an ‘Achilles’ 
heel’, can be improved through the refinement 
and interplay of various treatment options, includ-
ing the newly developed FCSEMS.
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